Browse Health
Cardiologist (heart)
22 years of experience
Accepting new patients


Education ?

Medical School
Aga Khan Medical College (1990)
Foreign school
University of Pittsburgh Medical Center *
Cardiovascular Disease
The University of Texas at Galveston *
Interventional Cardiology
* This information was reported to Vitals by the doctor or doctor's office.

Awards & Distinctions ?

American Board of Internal Medicine

Affiliations ?

Dr. Pohwani is affiliated with 4 hospitals.

Hospital Affiliations



  • Oak Valley Hospital District
    350 S Oak Ave, Oakdale, CA 95361
    Top 25%
  • Doctors Medical Center of Modesto
    1441 Florida Ave, Modesto, CA 95350
    Top 50%
  • Lodi Memorial Hospital
    975 S Fairmont Ave, Lodi, CA 95240
  • Memorial Medical Center Modesto
    1700 Coffee Rd, Modesto, CA 95355
  • Publications & Research

    Dr. Pohwani has contributed to 2 publications.
    Title Intermittent Outpatient Ultrafiltration for the Treatment of Severe Refractory Congestive Heart Failure.
    Date June 2005
    Journal Journal of Cardiac Failure

    BACKGROUND: Patients with severe congestive heart failure (CHF) become refractory to conventional medical therapy, leading to recurrent rehospitalizations. We examined the impact of intermittent outpatient ultrafiltration (UF), using either peritoneal dialysis or hemofiltration, on long-term clinical outcomes in patients with refractory CHF. METHODS AND RESULTS: We analyzed clinical and hemodynamic data in 19 consecutive patients with refractory CHF who received intermittent outpatient UF for at least 1 year between July 1998 and November 2002. The mean left ventricular ejection fraction of all 19 patients was 30.2 +/- 19.0%. All patients (100.0%) were New York Heart Association (NYHA) class IV. Only 5 patients (26.3%) received peritoneal dialysis; the remaining 14 (73.7%) received hemofiltration. There were 6 patients with a normal left ventricular ejection fraction (45%). After UF was started, the number of patients that were considered inotrope-dependent was reduced from 86.4% to 36.8% (P < .005). Compared with the year before UF was initiated, the number of CHF hospitalizations during follow-up was reduced from 2.6 to 0.3 (P < .005), and the NYHA class was improved from 4 to 3.1 (P < .005). Among all patients, 2 deaths were related to complications of UF, and cumulative 1-year survival was 63.2%. CONCLUSION: Our study suggests that UF is a safe, feasible therapy, but it needs further evaluation in carefully designed, prospective, randomized clinical trials. UF has the potential for offering another important therapeutic option for patients with severe and refractory CHF.

    Title Impact of Beta-blocker Therapy on Functional Capacity Criteria for Heart Transplant Listing.
    Date May 2003
    Journal The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation

    BACKGROUND: Peak exercise oxygen consumption is a widely used parameter to determine the need for transplant listing in patients with severe heart failure. Currently, beta-blocker therapy is known to benefit patients with severe heart failure, although it has minimal or no effects on peak exercise oxygen consumption. This raises the hypothesis that peak exercise oxygen consumption transplant-listing criteria are not valid for patients with heart failure who receive beta-blocker therapy. METHODS: We compared outcomes in patients with chronic heart failure who underwent heart transplant evaluation with peak exercise oxygen consumption </= 14.0 ml/kg/min and who were treated with beta-blockers (n = 48) or who were not treated with beta-blockers (n = 55). RESULTS: Outcomes were significantly better for patients treated with beta-blockers (combined end-points of death, transplantation as United Network for Organ Sharing [UNOS] Status 1 or 2, and ventricular assist device placement, p = 0.0001). The 1-year survival was 92% and 3-year survival was 71% in the patients treated with beta-blockers, and 69% and 48% in the patients not treated with beta-blockers (compared with UNOS transplant survival data of 92% 1-year and 77% 3-year survival rates). CONCLUSIONS: Patients with chronic heart failure and severe functional impairment who were treated with beta-blockers have significantly better outcomes compared with similarly functionally impaired patients who were not treated with beta-blockers, and these patients would not be expected to derive a survival benefit from transplantation. Thus, in patients treated with beta-blockers, the use of peak exercise oxygen consumption as a criterion to list for heart transplantation may no longer be valid. Alternatively, non-usage of beta-blockers may be a criterion to list for transplantation.

    Similar doctors nearby

    Dr. Charles Tsai

    Internal Medicine
    23 years experience
    Modesto, CA

    Dr. Peter Lai

    Internal Medicine
    36 years experience
    Modesto, CA

    Dr. Raman Moradkhan

    22 years experience
    Modesto, CA

    Dr. Syed Ahmed

    Internal Medicine
    16 years experience
    Modesto, CA

    Dr. Mutahir Khan

    Internal Medicine
    13 years experience
    Modesto, CA

    Dr. Isao Tsuji

    Internal Medicine
    42 years experience
    Modesto, CA
    Search All Similar Doctors